Trial · NCT07904182
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
NCT07904182, Not applicable, Recruiting, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer. Trials, record NCT07904182. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904182
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
- NCT number
- NCT07904182
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Cervical Cancer
- Interventions
- Absorbable Hydrogel Spacer
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative Rectal D2cc During the Full Course of Radiotherapy | From the start of EBRT through completion of the final IGBT fraction, approximately 7-8 weeks | Cumulative dose to the most exposed 2 cm³ of the rectum (D2cc) from external beam radiotherapy (EBRT) and all image-guided brachytherapy (IGBT) fractions, expressed as equivalent dose in 2-Gy fractions (EQD2) using an α/β ratio of 3 Gy. The cumulative rectal D2cc will be analyzed as a continuous variable. |
| Secondary | Proportion of Participants With Cumulative Rectal D2cc EQD2 ≤65 Gy | Through completion of the final IGBT fraction, approximately 7-8 weeks | Proportion of participants with cumulative rectal D2cc ≤65 Gy EQD2, calculated from EBRT and all IGBT fractions using an α/β ratio of 3 Gy. |
| Secondary | Change in Rectal D2cc Between Pre-Spacer and Post-Spacer EBRT Plans | From T0-CT before hydrogel implantation to T1-CT before the first EBRT fraction, approximately 1-7 days | Within-participant change in rectal D2cc between the research pre-spacer virtual EBRT plan generated using T0-CT and the clinical post-spacer EBRT plan generated using T1-CT under standardized planning conditions. The change in rectal D2cc will be reported in Gy. |
| Secondary | Proportion of Participants Completing the Planned Hydrogel-Assisted Radiotherapy Workflow | From hydrogel implantation through completion of the final IGBT fraction, approximately 7-8 weeks | Proportion of participants who successfully undergo hydrogel implantation and complete the planned EBRT and IGBT workflow without clinically meaningful treatment interruption attributable to the study procedure. |
| Secondary | Proportion of Participants With Procedure- or Device-Related Adverse Events | From hydrogel implantation through 12 months after completion of radiotherapy | Proportion of participants experiencing adverse events or serious adverse events considered related to hydrogel implantation, the device, or the implantation procedure. Adverse events will be graded according to CTCAE version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904182
GET https://conductscience.org/api/trials/v1/NCT07904182/registered